Index

ABC of trials, 1
Akaike Information Criteria (AIC), 133–5
aggregate cluster level
  summaries, 83–101, 131, 133, 201–2, 213
analysing cRCT outcomes, 83–101
  binary outcomes, 94–5
  Mann–Whitney U-test, 91–4
  matched design, 95–8
  statistical analysis, 84, 86–91
  two independent-samples t-test, 86–9
analysis of covariance (ANCOVA), 186
analysis of variance (ANOVA), 16, 22, 74
area under the curve (AUC), 192
auto-correlation, 114–15, 223
autoregressive correlation matrix, 218
baseline, 8, 12, 72, 192
baseline assessment, 192
Bayesian methods, 109
baseline covariates adjustment for, 115, 172
between cluster variability, 175
bias, 128, 185
binary outcomes, 18–20, 94–5, 205–6, 209–10
binomial distribution, 18
blinding, 151, 163
block randomisation, 2, 43, 48
block size, 43–4, 48, 162
Bonferroni correction, 73, 193–4
bootstrap method, 51, 120
central limit theorem, 85
chi-square test, 57, 59, 94, 225
clinical significance, 152
clinically important difference, 75
cluster level analysis, 84–6, 98–9, 201–2, 213–15
cluster level data, 102
cluster level t-test, 131
cluster randomised controlled trial (cRCTs), 4, 50–83, 102, 126–42, 153, 159–77, 232
cluster size fixed, 69
cluster trials, 53
crossover trials, 75–6
equivalence/non-inferiority studies, 64–6
justification/requirement, 51
matched-pair studies, 72–3
multiple outcomes/endpoints, 73–4
post hoc sample size calculations, 75
practical problems, 67–8
cluster randomised controlled trial (cRCTs)

prevention, 178–81
reporting of, 159–77
sample size, binary data, 56–9
categorical data, 59–62
continuous data, 53–6
rates, 62–3
re-estimation, 71–2
survival, 64
significance tests, P-values, 51–3
three or more groups, 74
unknown standard deviation and effect size, 66–7
values of ICC, 69–70
cluster size, 68–71, 98, 110
cluster specific effects, 104–5
cluster specific model, 127–9
cluster specific odds ratio, 129
cluster summary statistics, 83, 87, 89, 210–202
cluster-cluster trial, 5, 22
coefficient of variation, 19–20, 63, 71
coefficient of variation of cluster size, 20, 71
cohort design, 11–12
cohort trial, 5, 8–11
DESMOND trial, 9–10
diabetes care from diagnosis trial, 10–11
PoNDER trial, 8–9
REPOSE trial, 11
COMMl trial, 35
community intervention trials, 35, 121
complete-case analysis, 186
complex intervention, 3–4, 30–33, 181–4
complex intervention phases of development, 181–2
confidence intervals, 100, 225
confounders, 120, 152
consent, 148, 154–5
CONSORT, 4, 103, 145, 159–61, 166
CONSORT checklist for cluster RCTs, 161–5
CONSORT flow chart, 166
CONSORT statement, 145, 159–60, 174–5
construct validity, 44
contamination, 12
continuous outcomes, 15–18, 86–8, 102–5, 202–5, 208–9
control arm, 34
correlation, 82, 85, 104, 114
count outcomes, 206–8, 210–212
counterfactual, 108
covariates, 72, 115, 223
cross-over trials, 38–9, 75, 81
cross-sectional analysis, 121, 119–21
data collection, 149–50
data monitoring committee, 152–3
degrees of freedom, 35–6, 202
design effect, 20–21, 23, 54–5, 85, 139
DESMOND trial, 9–10, 172
device, 132–3
Diabetes Care from Diagnosis trial, 10–11
dotplots, 87, 90
drop outs, 8
Edinburgh Postnatal Depression Score (EPDS), 103, 131, 145, 167
effect size (ES), 66–7
eligibility, 148–9
equivalence trials, 30
estimation, method parameters, 130
ethics, 153–5
ethics committee, 153
exchangeable auto-correlation, 115, 223
explanatory trial, 28–9
factorial trials, 37–8
Family Heart Study, 36–7
F-distribution, 109
feasibility study, 33
field trial, 5–6
fixed effects, 104–5
flow chart, 166
forest plots, 172, 174
general linear model, 112–14
generalised least squares, 109
generalised estimating equations (GEE), 84, 102, 112–14, 135, 141, 208
global tests, 193–4
group allocation, 179–80
group randomisation, 145

Health Related Quality of Life (HRQoL), 28
heterogeneity, 15, 86
histogram, 87, 103
history of cluster randomised trials, 4
HOOP trial, 21
Hotelling $T^2$ test, 193
homogeneity, 106
hypothesis testing, 73–4, 120, 166

imputed data, 187
incomplete data, 167–71
informed choice leaflets trial, 6–7, 13
intention-to-treat (ITT) analysis, 29
interaction, 37–8, 120, 171
intra-class correlation, 58
intra cluster correlation (ICC), 16–19, 54, 56, 65, 69–70, 175
inverse variance weight, 85

last-observation carried forward (LOCF), 186–90
least squares, 104, 109
iterative re-weighted least squares, 120
linear regression, 84, 105–8, 110, 113–15
link function, 127, 135, 219
logistic regression, 129–30, 132–4
longitudinal data, 186

Mann–Whitney $U$-test, 59, 76, 83, 91–4
marginal general linear model, 112–14
marginal models, 112, 127–8, 184, 209–12, 215–26
matching, 35–6, 72
maximum likelihood, 109, 120, 202, 227
mean, 15–16, 18–19
median, 19, 43, 48, 64, 94
minimisation, 44–5
minimum clinically important difference (MCID), 75
missing at random (MAR), 186
missing completely at random (MCAR), 186
missing data, 139, 185–9
MRC complex intervention, 181–4
multiple comparisons, 73–4, 192–4
multiple endpoints, 73–4
multiple imputation, 139, 186
multiplicity of outcomes, 73–4, 192–4
comparison of procedures question of, 194
confirmatory tests, 192
global tests and multiple comparison procedures, 193–4
summary measures and statistics, 193
Mwanza trial, 7, 95, 98

non-inferiority trials, 30, 64
non-parametric methods, 91
non-parametric tests, 76
non-response, 67
normal distribution, 54, 87, 106, 109, 118, 127, 225
null hypothesis, 51–2, 64, 74, 90–93

odds ratio (OR), 20, 56, 61, 79–80, 128
ordered categorical data, 79–80
ordinal data, 59–62
example calculations, 60–62
sample size formula, 59–60
ordinary least squares, 104

paired data, 25–6
paired $t$-test, 95, 100–101
paramedics practitioner trial, 7–8
parametric methods, 91–2
PEACH trial, 156–7
Pearson correlation coefficient, 17–18
per-protocol analysis, 29
phases of a trial, 28–9
phase I trials, 28, 32
phase II trials, 28–9
phase III trials, 28–9
phase IV trials, 28
pilot study, 33
placebo, 2–3, 28
Poisson regression, 126, 135, 141–2, 211
PoNDER trial, 8–9, 113, 145, 160, 172, 210, 213, 224–5, 227, 231
population-averaged model, 84, 102, 107–8, 124
post-hoc sample size calculations, 75
power, 51–2, 61, 75
pragmatic trial, 28–9
precision, 41–2
prognostic factors, 2, 35, 42, 45
proportions, difference between, 56–9
protocol, 143–56
abstract, 144–5
assessment and data collection, 149–50
background, 147
design, 147–8
eligibility, 148–9
ethics, 153–5
intervention details, 148
organization, 155–6
outcome measures, 147
randomisation, 149
research objectives, 147
statistical considerations, 150–153
pseudorandomised trials, 40–41
P-values, 51–3
Q–Q plot, 110, 117–18
R software, xiii, 195–9
random effects models, 15, 227–32
binary outcomes, 205–6
continuous outcomes, 202–5
count outcomes, 206–8
random effects models for binary outcomes, 18–20
coefficient of variation, 19–20
ICC for binary data, 19
model, 18
relationship between cvc and ρ for binary data, 20
random effects models for continuous outcomes, 15–18
intraclasse correlation coefficient (ICC), estimating, 16–17
intracluster correlation coefficient, 16
model, 15–16
Pearson correlation coefficient and ICC, link between, 17–18
random intercept model, 15, 108
randomisation, 2, 42–5, 149, 162
minimisation, 44–5
reasons, 2, 42
restricted, 2, 43–4
simple, 2, 43
stratified, 2, 43
randomised controlled trial (RCT), 1–3, 30, 51
allocation at random, 1–2
blinding, 2
control, 2–3
rates, 62–3
REACT trial, 5–6
reasons for cluster trials, 12–14
recruitment, 151, 155, 164, 179–81
recruitment bias, 34
prevention, 179–81
regression analysis, 83, 102
regression imputation, 188
relative risk, 20, 56
reporting, 171–6
REPOSE trial, 11, 34
residuals, 109–10
restricted maximum likelihood estimation (REML), 130, 204, 227, 233
retention, 183
robust standard errors, 105–7
robust variance estimator, 106, 121
sample size estimation/calculation, 50, 69–70, 75
selection bias, 41, 180
selection of individuals, 33, 133
SF-36, 55, 58, 65, 152, 192–3
significance (statistical), 51, 73, 166
significance level, 21, 52, 68, 71
significance tests, 51–3, 74
small numbers of clusters, 56, 76
SPSS, xiii, 212–32
standard deviation (SD), 19, 53, 105
standard error, 83, 135
Stata, xiii, 199–12, 232
‘stepped’ wedge design, 39–40
stratification, 45
subgroup analyses, 152
summary measures/statistics at cluster level, 131–2, 193
superiority trial, 30, 64
survival outcomes, 63
three or more groups, 74
time to event outcomes, 126–42
  cluster trials, survival analysis with, 137–9
  cluster-specific model versus population-averaged/ or marginal model, 127–9
count data, analysis, 135–7
logistic regression, binary data analysis using, 132–4
  marginal models, 135
  missing data, 139
  random-effects logistic regression, 134–5
review of past simulations, 130–131
summary measures, analysis using, 131–2
treatment groups t-test, 57
treatment × time interaction, 120
t-test unequal variances, 106, 132
t-test weighted, 90–91
t-test with Satterthwaite’s correction, 202
t-test with Welch’s correction, 202
two independent samples t-test, 86
type I error, 52–3
type II error, 52–3
UK MRC framework for complex interventions, 182
unit non-response, 67
unit of analysis, 50
unmatched analysis of unmatched data, 35
variance, 15–16, 19–20
variance inflation factor (VIF), 20
Welch test, 91, 132, 202
weighted t-test, 90–91
weighting in analysis, 91, 120, 133
Wilcoxon matched pairs test, 100–101
Wilcoxon rank sum test, 95, 99
within-cluster variance, 14, 16, 20
within-cluster homogeneity, 106